Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)

Praxis Precision Medicines' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $1.2 million for Q3 2024.

• In Q3 2024, Current Deferred Revenue fell 24.61% year-over-year to $1.2 million; the TTM figure through Sep 2024 stood at $1.2 million (down 24.61% YoY), while the FY2023 annual figure was $1.4 million, down 72.16% from the prior year.
• Current Deferred Revenue was $1.2 million for Q3 2024 at Praxis Precision Medicines, down from $1.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $5.0 million in Q4 2022 to a low of $1.2 million in Q3 2024.
• Historically, Current Deferred Revenue has averaged $2.0 million across 3 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue slumped 72.16% in 2023, then slipped 24.61% in 2024.
• A 3-year view of Current Deferred Revenue shows it stood at $5.0 million in 2022, then plunged by 72.16% to $1.4 million in 2023, then slipped by 15.95% to $1.2 million in 2024.
• The last three Current Deferred Revenue figures came in at $1.2 million (Q3 2024), $1.2 million (Q2 2024), and $1.3 million (Q1 2024), per Business Quant data.